Syntaxin 1: A Novel Robust Immunophenotypic Marker of Neuroendocrine Tumors by Kővári, Bence et al.
 International Journal of 
Molecular Sciences
Article
Syntaxin 1: A Novel Robust Immunophenotypic
Marker of Neuroendocrine Tumors
Bence Ko˝vári 1,*,† , Sándor Turkevi-Nagy 1,†, Ágnes Báthori 1, Zoltán Fekete 1
and László Krenács 2
1 Department of Pathology, University of Szeged, Szeged 6725, Hungary;
turkevi-nagy.sandor@med.u-szeged.hu (S.T.-N.); bathori.agnes87@gmail.com (Á.B.);
z0li950912@gmail.com (Z.F.)
2 Laboratory of Tumor Pathology and Molecular Diagnostics, Szeged 6726, Hungary; krenacsl@vipmail.hu
* Correspondence: kovari.bence.p@gmail.com
† These authors contributed equally to this work.
Received: 4 December 2019; Accepted: 10 February 2020; Published: 12 February 2020


Abstract: Considering the specific clinical management of neuroendocrine (NE) neoplasms (NENs),
immunohistochemistry (IHC) is required to confirm their diagnosis. Nowadays, synaptophysin (SYP),
chromogranin A (CHGA), and CD56 are the most frequently used NE immunohistochemical markers;
however, their sensitivity and specificity are less than optimal. Syntaxin 1 (STX1) is a member of
a membrane-integrated protein family involved in neuromediator release, and its expression has
been reported to be restricted to neuronal and NE tissues. In this study, we evaluated STX1 as
an immunohistochemical marker of NE differentiation. STX1, SYP, CHGA, and CD56 expression
was analyzed in a diverse series of NE tumors (NETs), NE carcinomas (NECs), and non-NE tumors.
All but one (64/65; 98%) NETs and all (54/54; 100%) NECs revealed STX1 positivity in at least 50% of
the tumor cells. STX1 showed the highest sensitivity both in NETs (99%) and NECs (100%) compared
to CHGA (98% and 91%), SYP (96% and 89%), and CD56 (70% and 93%), respectively. A wide variety
of non-NE tumors were tested and found to be uniformly negative, yielding a perfect specificity.
We established that STX1 is a robust NE marker with an outstanding sensitivity and specificity.
Its expression is independent of the site and grade of the NENs.
Keywords: neuroendocrine neoplasia; neuroendocrine tumor; neuroendocrine carcinoma;
immunohistochemistry; syntaxin 1
1. Introduction
Neuroendocrine (NE) cells comprise a cellular network integrating the nervous and endocrine
systems. They are found in virtually all organs, and the most common are in the gastrointestinal and
lower respiratory tracts. The NE cells secrete biogenic amines and peptide hormones regulating a wide
variety of functions into the bloodstream. Tumorous growths of NE cells are collectively referred
to as NE neoplasms (NENs). The bioactive substances secreted by neoplastic NE cells can lead to
distinct clinical syndromes. Although the NENs may follow an indolent clinical course, a significant
number of patients are diagnosed with advanced disease. Although there are many organ-specific
differences in tumor biology and prognostic factors among NENs of different localizations, according
to the recommendations of the International Agency for Research on Cancer (IARC) and World Health
Organization (WHO) expert consensus proposal, the terminology of NENs should be uniformized
in the future. Therefore, the currently substantially differing organ-specific classification schemes of
NENs will be potentially revised and harmonized within the next edition of each WHO Blue Book [1,2].
This proposal separates well-differentiated and poorly differentiated NENs. The well-differentiated
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NENs are also referred to as NE tumors (NETs), while poorly differentiated highly malignant NENs
are also designated as NE carcinomas (NECs) ([2,3] (pp. 210–214), [4] (pp. 18–19)). The histopathologic
diagnosis of NENs is based on the typical cytomorphological and architectural features of these
tumors; nevertheless, in atypical and especially poorly differentiated cases, immunophenotyping is
inevitable [5–7]. Rare tumors with two distinct NE and non-NE cell populations, in which either
component represents at least 30%, are defined as a mixed neuroendocrine-non-neuroendocrine
neoplasm (MiNEN) [4] (pp. 16–20). These cases may be difficult to recognize, particularly when
they are poorly differentiated, and their accurate classification also requires immunohistochemistry
(IHC) evaluation.
NE cells share common antigens characteristic of NE differentiation, which can be utilized as
immunophenotypic markers. Some of these are rather obsolete, such as the neuron-specific enolase (NSE)
and protein gene product 9.5 (PGP9.5), which are very sensitive, but seriously lack specificity [6,8]; others,
such as synaptophysin (SYP), chromogranin-A (CHGA), CD56, and insulinoma-associated protein 1
(INSM1), are more reliable, but still show disadvantages when used as individual markers [8–15].
Syntaxin 1 (STX1) is a member of a membrane-integrated nervous system-specific protein
superfamily involved in the neuromediator release from synaptic vesicles [16–18]. STX1 plays a crucial
role in ion channel regulation and synaptic exocytosis [16–18]. Two STX1 isoforms, HPC-1/syntaxin
1A and syntaxin 1B, are thought to have similar functions in the exocytosis of synaptic vesicles and
show a very high homology [19,20]. Additionally, it has been reported that STX1 is associated with
chromaffin granules in the adrenal medulla [21] and expressed in alpha, beta, and delta cells of
pancreatic islets [22,23]. Using a Web-based in silico biomarker analysis, syntaxin 1A protein expression
has been found to be restricted to NE cells [24]; however, this finding was not further evaluated.
Since STX1 represents a promising NE marker and has not yet been comprehensively tested in
diagnostic pathology, we performed a retro- and prospective IHC study on a diverse series of benign
and malignant tumors, in order to establish its utility in the immunophenotyping of NENs.
2. Results
Virtually all normal NE cells and hyperplastic NE lesions showed strong membranous and weak
to moderate cytoplasmic STX1 staining (Figure 1). Thyroid follicular cells, adrenocortical tissue,
and non-NE cells, including gastrointestinal mucosa, exocrine pancreas, liver, kidney, lymphoid
tissue, and skin, showed no STX1 positivity. Neuronal tissue in the brain and peripheral nerves,
including hypertrophic myenteric plexus in appendicitis specimens, revealed consistent STX1 staining.
The results obtained with STX1 in NE and neuroepithelial neoplastic samples are summarized in
Table 1.
Table 1. STX1, chromogranin A (CHGA), synaptophysin (SYP), and CD56 immunoreactivity of NE
neoplasms (NENs) and neuroectodermal/neuroepithelial neoplasms.
Gastrointestinal NETs STX1 CHGA SYP CD56
Gastric enterochromaffin-like (ECL) cell NET 5/5 100.0% 4/4 100.0% 3/3 100.0% 0/1 0.0%
Duodenal non-functioning NET 2/2 100.0% 2/2 100.0% 2/2 100.0% na na
Ampullary NET 1/2 50.0% 2/2 100.0% 1/2 50.0% 1/2 50.0%
Small intestinal enterochromaffin (EC) cell
NET 12/12 100.0% 12/12 100.0% 12/12 100.0% 8/12 66.7%
Appendix NET 9/9 100.0% 8/8 100.0% 7/7 100.0% 9/9 100.0%
Rectal EC cell NET 2/2 100.0% 2/2 100.0% 1/1 100.0% 0/2 0.0%
Rectal L cell NET 5/5 100.0% 2/5 33.3% 4/4 100.0% 5/5 100.0%
Metastatic NET. gastrointestinal origin 4/4 100.0% 4/4 100.0% 1/2 50.0% 0/2 0.0%
Pancreatic NETs
Pancreatic functioning NET * 3/3 100.0% 2/2 100.0% 2/2 100.0% 1/1 100.0%
Pancreatic non-functioning NET 16/16 100.0% 13/14 92.9% 12/13 92.3% 10/11 90.9%
Pulmonary carcinoids
Pulmonary carcinoid. typical 3/3 100.0% 3/3 100.0% 2/2 100.0% 2/2 100.0%
Pulmonary carcinoid. atypical 2/2 100.0% na na na na na na
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Table 1. Cont.
Gastrointestinal NETs STX1 CHGA SYP CD56
Gastroenteropancreatic NECs
Stomach small cell NEC 2/2 100.0% 1/1 100.0% 1/1 100.0% 1/1 100.0%
Duodenal large cell NEC 1/1 100.0% 1/1 100.0% 1/1 100.0% na na
Pancreatic large cell NEC 2/2 100.0% 1/1 100.0% 1/1 100.0% 2/2 100.0%
Ampullary small cell NEC 2/2 100.0% 1/1 100.0% na na 2/2 100.0%
Pulmonary NECs
Pulmonary small cell NEC 19/19 100.0% 9/10 90.0% 2/2 100.0% 16/16 100.0%
Pulmonary large cell NEC 4/4 100.0% 1/1 100.0% na 2/2 100.0%
Etc NECs
Merkel cell carcinoma 5/5 100.0% 1/1 100.0% 1/1 100.0% 2/2 100.0%
Medullary thyroid carcinoma 10/10 100.0% 5/5 100.0% 2/2 100.0% 3/3 100.0%
Metastatic small cell NEC with unknown
primary 3/3 100.0% na na na na 2/2 100.0%
Metastatic large cell NEC with unknown
primary 3/3 100.0% 3/3 100.0% na na 1/3 33.3%
Small cell NEC of the prostate 1/1 100.0% 1/1 100.0% 1/1 100.0% 1/1 100.0%
Small cell NEC of the uterine cervix 1/1 100.0% na na na na na na
Small cell NEC of the breast 1/1 100.0% na na na na na na
Tumors with mixed NE and non-NE
components **
MiNEN ** 2/2 100.0% 0/1 0 2/2 100.0% 0/2 0.0%
Mixed tumor with minor NE component ** 4/4 100.0% na na 2/2 100.0% 0/2 0.0%
Etc NENs
Pituitary adenoma 19/19 100.0% 4/4 100.0% 1/1 100.0% na na
Pheochromocytoma/paraganglioma 16/18 88.9% 15/16 93.8% 9/10 90.0% 2/2 100.0%
Neuroectodermal/neuroepithelial neoplasia
Medulloblastoma 8/9 88.9% na na 8/9 88.9% 2/2 100.0%
Neuroblastoma 8/8 100.0% 5/5 100.0% 5/5 100.0% 2/2 100.0%
Ganglioneuroma 2/2 100.0% na na na na na na
Ewing sarcoma/PNET 2/2 100.0% na na na na na na
*: 2 insulinomas, 1 gastrinoma. **: the component showing an NE morphology was positive, and the non-NE
component was negative for STX1.
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Figure 1. Syntaxin 1 (STX1) immunoreactivity in non-neoplastic tissues. (A) Nodular neuroendocrine 
(NE) cell hyperplasia in autoimmune metaplastic atrophic gastritis, 10x; (B) NE cells in normal colonic 
mucosa, 20x; (C) Langerhans islets in normal pancreatic tissue, 10x; (D) NE cells in normal bronchial 
mucosa, 40x.  
Figure 1. Syntaxin 1 (STX1) immunoreactivity in non-neoplastic tissues. (A) Nodular neuroendocrine
(NE) cell hyperplasi in autoimmune metaplastic atrophic gastritis, 10x; (B) NE cells in normal colonic
mucosa, 20x; (C) Langerhans islets in normal pancreatic tissue, 10x; (D) NE cells in normal bronchial
mucosa, 40x.
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All but one (99/100, 99%) cases of NENs, including metastatic NETs, proved to be STX1-positive
(Figure 2). Regarding specific subsets of gastrointestinal NETs, vesicular monoamine transporter 1
(VMAT1)-positive EC cell NETs; VMAT1-negative, autoimmune gastritis-associated NETs consistent
with ECL cell NETs; and even rectal glucagon-like peptide 1 (GLP1)-positive L cell NETs, were
consistently positive (Figure 3). At least 50% of the tumor cells were labeled with a moderate to strong
intensity, but in 92% of cases, the positivity rate was more than 85%. The STX1 staining intensity
showed no correlation with the mitotic activity, Ki-67 labeling index, or tumor grade. The single
STX1-negative case represented a grade 2 CHGA-positive NET of the major duodenal papilla. All small
and large cell NECs were consistently STX1-positive, mostly with intense diffuse staining, regardless of
the anatomical site (Figure 4). Furthermore, special types of NECs, such as Merkel cell and medullary
thyroid carcinomas, similarly showed uniform strong diffuse immunoreactivity for STX1 (Figure 5).
The staining pattern was usually both membranous and cytoplasmic. The ratio of these two
patterns varied considerably, from predominantly cytoplasmic to complete diffuse membranous.
Membrane staining was typically complete in NETs, although in some cases with an acinar architecture,
a basolateral membranous staining pattern was revealed. In some NECs, predominantly aberrant
incomplete membrane staining was noticed. In comparison to common NE IHC markers, STX1 showed
the highest sensitivity both in NETs (99%) and NECs (100%), which was followed by CHGA (98%
and 91%), SYP (96% and 89%), and CD56 (70% and 93%), respectively (Table 2). The four applied
markers detected a significantly different proportion of positive cases regarding gastrointestinal NETs
(p < 0.000001), gastrointestinal NECs (p = 0.01), and NECs in general (p = 0.007). In terms of pancreatic
NETs, no statistically significant level of such an association was seen.
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Figure 2. CD56, CHGA, SYP, and STX1 immunoreactivity in a pancreatic non-functioning NE tumor 
(NET) grade 2. (A) CD56, 20x; (B) CHGA, 20x; (C) SYP, 20x; (D) STX1, 20x. 
Figure 2. CD56, CHGA, SYP, and STX1 immunoreactivity in a pancreatic non-functioning NE tumor
(NET) grade 2. (A) CD56, 20x; (B) CHGA, 20x; (C) SYP, 20x; (D) STX1, 20x.
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Figure 3. STX1 (A, C) vesicular monoamine transporter 1 (VMAT1), (B) and glucagon-like peptide 1 
(GLP1) (D) immunoreactivity in a small intestinal enterochromaffin (EC) cell NET grade 2 (A, B) and a 
rectal L cell NET grade 1 (C, D). 20x. 
 
Figure 3. STX1 (A,C) vesicular monoamine transporter 1 (VMAT1), (B) and glucagon-like peptide 1
(GLP1) (D) immunoreactivity in a small intestinal enterochromaffin (EC) cell NET grade 2 (A,B) and
a rectal L cell NET grade 1 (C,D) 20x.
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 6 of 15 
 
 
Figure 3. STX1 (A, C) vesicular monoamine transporter 1 (VMAT1), (B) and glucagon-like peptide 1 
(GLP1) (D) immunoreactivity in a small intesti  nterochromaffin (EC) cell NET grade 2 (A, B) and a 
rectal L cell NET grade 1 (C, D). 20x. 
 
Figure 4. CD56, CHGA, SYP, and STX1 immunoreactivity in a pancreatic large cell NE carcinoma
(NEC). (A) CD56, 20x; (B) CHGA, 20x; (C) SYP, 20x; (D) STX1, 20x.
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Figure 5. STX1 immunoreactivity in various types of NECs. (A-C) Hematoxylin-eosin stainings; (D-
F) STX1 immunohistochemistry (IHC) reactions; (A,D) small cell NEC of the lung, 20x; (B,E) 
medullary thyroid carcinoma, 20x; (C,F) Merkel cell carcinoma of the skin, 10x. 
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STX1 expression was generally absent in conventional carcinomas. In a subset (16/215, 7%) of 
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population was noticeable without a definite NE morphology. The expression of at least one further 
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Figure 5. STX1 immunoreactivity in various types of NECs. (A–C) Hematoxylin-eosin stainings; (D–F)
STX1 immunohistochemistry (IHC) reactions; (A,D) small cell NEC of the lung, 20x; (B,E) medullary
thyroid carcinoma, 20x; (C,F) Merkel cell carcinoma of the skin, 10x.
Table 2. Sensitivity of STX1, CHGA1, SYP, and CD56 in NETs and NECs.
Sensitivity—NET Sensitivity—NEC
STX1 99% 100%
CHGA 98% 91%
SYP 96% 89%
CD56 70% 93%
In six tumors with mixed NE and non-NE components, including those ith only minor NE
components and those qualifying as MiNENs, the STX1 expression topographically always colocalized
with the morphologic l features of NE differentiation (Table 1), while the exocrine component showed
no STX1 positivity.
STX1 expression was generally absent in conventional carcinomas. In a subset (16/215, 7%) of
conventional (non-NE) neoplasia, a discrete (<10%) and scattered intratumoral STX1-positive cell
population was noticeable without a definite NE morphology. The expression of at least one further
(CD56, SYP, or CHGA) NE marker was also detected in all these cases. The majority (10/13, 77%) of the
hypercellular variant (type B) of mucinous breast carcinoma cases and one case of ductal carcinoma
demonstrated STX1 positivity, usually in more than 60% of the tumor cells (Table 3).
All 20 (100%) pituitary adenoma cases and 14/16 (88%) of pheochromocytoma cases showed STX1
positivity (Table 1, Figure 6). The latter tumor group included 12 cases with diffuse staining and two
cases with 30% tumor cell positivity. The two STX1-negative medullary chromaffin cell-derived tumors
represented one benign and one malignant pheochromocytoma case. In three pheochromocytomas,
faint and focal STX1 positivity was also exhibited by the sustent cular cells. Endocrine neoplasias,
including adrenoco tic l denoma and adre cortical carcino a, parathyroid adenoma, papillary
thyroid arcinoma, and follicular thyroid adenoma cases, were consistently STX1-negative (Table 3).
All but one neuroectodermal/neuroepithelial tumor samples revealed strong diffuse STX1 positivity
in neuroblasts and ganglion cells (Table 1), whereas less than 10% of tumor cells were positive in
one medulloblastoma case. Where it was present, the neuropil component also showed a moderate
expression. The Schwann cell component of the ganglioneuromas, and all peripheral nerve sheet
tumor cases, proved to be STX1-negative (Table 3). Scattered STX1-positive tumor cells were found in
2/2 Ewing family tumor cases studied.
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Table 3. STX1 immunoreactivity in conventional (non-NE) tumors.
Tumor Type STX1 (Positive/TotalNo. of Cases; %)
No. of Cases with Scarcely
Scattered STX1 Positive Cells
Colorectal adenocarcinoma 0/8 0.0% 5
Gastric adenocarcinoma 0/12 0.0% 9
Hepatobiliary and pancreatic carcinoma 0/11 0.0% 1
Lung squamous cell carcinoma 0/5 0.0%
Lung adenocarcinoma 0/8 0.0%
Head and neck carcinoma 0/7 0.0%
Basal cell carcinoma of the skin 0/2 0.0%
Cervical and ovarian carcinoma 0/8 0.0% 1
Prostatic adenocarcinoma 0/7 0.0%
Melanocytic tumor 0/9 0.0%
Soft tissue tumor 0/13 0.0%
Lymphoma and myeloid neoplasm 0/31 0.0%
Genital germ cell tumor 0/9 0.0%
Gonadal sex-cord stromal tumor 0/5 0.0%
Solid pseudopapillary neoplasm (pancreas) 0/1 0.0%
Adrenocortical adenoma 0/11 0.0%
Adrenocortical carcinoma 0/12 0.0%
Parathyroid adenoma 0/19 0.0%
Papillary thyroid carcinoma 0/5 0.0%
Thyroid follicular adenoma 0/1 0.0%
Carcinomas of the breast
No special type 1/18 5.6% 1
Invasive lobular carcinoma 0/2 0.0%
Mucinous carcinoma, hypocellular type 0/6 0.0%
Mucinous carcinoma, hypercellular type 7/10 70.0%
Metaplastic carcinoma 0/1 0.0%
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3. Discussion
There are several IHC NE markers used in diagnostic pathology. To use these markers responsibly,
one should be aware of their advantages and limitations [12–15]. Currently, CD56, CHGA, and SYP
represent the most widely used NE markers. CD56 is highly sensitive to NE cells [4]; however, it is also
detectable in a heterogeneous group of non-NE neoplasms, including nephroblastoma, neuroblastoma,
myeloid, lymphoid, and plasma cell tumors, as well as in hepatocellular, renal cell, ovarian, endometrial,
and thyroid carcinomas [25,26]. Therefore, it is unreliable if used as a single marker. CHGA constitutes
a secretory granule protein of the NE, adenohypophyseal, and parathyroid cells [27,28]. As an IHC
NE marker, CHGA shows a good sensitivity; nevertheless, some NE cells, such as Merkel cells and
hindgut-derived NE cells [29], may demonstrate significantly weaker staining or can lack CHGA
immunoreactivity. Furthermore, the strong cytoplasmic expression seen in most NE cells may be weak
or absent in NECs, due to the low density of mature secretory granules [30,31]. SYP is an integral
membrane calcium-binding glycoprotein of synaptic vesicles. It is a sensitive marker usually expressed
in the cytoplasmic microvesicles of neuronal tumors, NENs, and neuroectoderm-derived small blue cell
tumors, as well as in many endocrine tissues, such as normal and neoplastic pituitary and parathyroid
glands and adrenocortical tissue [32–34].
In this study, we performed a comprehensive IHC analysis in an extensive series of benign and
malignant tumors to evaluate STX1 as an IHC NE marker. Using a well-characterized monoclonal
mouse antibody, we found that STX1 represents an impressive robust NE marker, with a sensitivity
of 99% in NETs and 100% in NECs, outperforming other common NE markers, such as SYP (96%
and 89%), CHGA (93% and 91%), and CD56 (70% and 93%), which was proven to be statistically
significant regarding gastrointestinal NETs and NECs. Normal NE cells in different organs, as well
as pulmonary, gastrointestinal, and pancreatic NETs and NECs, were likewise positive. Therefore,
the STX1 expression of NENs seems to be unrelated to the anatomical site. In contrast to the frequently
negative CHGA staining in rectal and appendiceal L-cell NETs [9–11], STX1 was consistently positive in
all such cases studied. Pheochromocytomas and paragangliomas were also almost consistently positive.
STX1 was uniformly expressed in all NECs, regardless of the morphological or clinicopathological
subtype, including small and large cell NECs, as well as in Merkel cell carcinomas and medullary
thyroid carcinomas. In contrast to the sometimes faint or dot-like cytoplasmic expression of SYP
and CHGA, the STX1 revealed crisp membranous and strong cytoplasmic staining in the majority of
cases studied, which makes the evaluation straightforward. Concerning the specificity of STX1, many
endocrine tumors known to express either CHGA or SYP, such as parathyroid and adrenocortical
neoplasms [35], were consistently negative for STX1. As further evidence of the excellent specificity of
STX1, a broad spectrum of non-NE tumors, including various types of carcinomas, were consistently
negative. In MiNENs and carcinomas with focal NE components, the STX1 immunostaining was
restricted to the NE areas, as was confirmed by other NE markers. A caveat is that in 7% of conventional
(non-NE) neoplasia, a discrete (<10%) and scarcely scattered STX1-positive cell population was present
without morphological features of NE differentiation. In our opinion, by correlating the IHC stains
to the histomorphology, these infrequent positive cells should not cause any diagnostic problem,
and such reactions should be interpreted as negative. Although STX1 was also expressed in neural
tumors, considering the rather distinct presentation of these neoplasms, the differentiation appears to
be straightforward.
INSM1 is a recently described IHC NE marker [36], demonstrating nuclear localization. It has
been studied in the NENs of many anatomical regions, including the lung, head and neck, central
nervous system, prostate, skin, and pancreas, but, according to the reported series, the INSM1 reveals
a lower sensitivity [13,36–41] than STX1 in our series. Although a direct comparison of the two markers
is warranted in future studies, based on the literature data and results of the present study, STX1
outperforms INSM1 in terms of its specificity and sensitivity.
In keeping with the frequent NE differentiation of hypercellular (type B) mucinous breast
carcinomas, a small cohort of these tumors were also stained positive for STX1, while breast cancer
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types infrequently expressing NE markers, such as hypocellular (type A) mucinous, conventional
invasive ductal, and lobular carcinomas, were negative. Due to the limited number of breast tumors
included in this study, additional investigations of breast cancer are warranted.
4. Materials and Methods
4.1. Samples Studied
All samples were assigned by the Department of Pathology, University of Szeged, and the
Laboratory of Tumor Pathology and Molecular Diagnostics, Szeged, Hungary, and represented
formalin-fixed paraffin-embedded (FFPE) tissues.
To study STX1 in non-neoplastic tissues, normal thyroid (8 samples), parathyroid (11 samples),
skin (2 samples), pancreas (5 samples), adrenal gland (9 samples), and brain tissue (5 samples), as well as
appendectomy specimens from acute appendicitis (5 cases), were evaluated. Hyperplastic NE lesions,
such as linear and nodular NE cell hyperplasia in autoimmune metaplastic atrophic gastritis (10 cases)
morphologically consistent with ECL cell hyperplasia [42] and one case of pancreatic nesidioblastosis,
were also included. In tumor samples, peritumoral non-neoplastic NE cells, including gastric antral
and oxyntic mucosal, as well as intestinal NE cells, pancreatic Langerhans islets, bronchial NE cells,
and cutaneous Merkel cells, were also assessed for STX1 expression, where they were present.
To evaluate the specificity and sensitivity of STX1 in neoplastic conditions, altogether, 398 cases of
various non-NE and NE neoplasms were studied (Table 1) in either whole tissue sections or tissue
microarrays (TMAs). Cases with potential diagnostic pitfalls, for example, frequently CHGA-negative
L cell NETs (three rectal and one appendiceal), were also included. In 6/215 cases of predominantly
non-neuroendocrine carcinomas, a component showing morphological features of neuroendocrine
differentiation was also present. In four (one colonic and one diffuse gastric adenocarcinoma, one
poorly differentiated squamous cell, and one adenocarcinoma of the lung) cases, the neuroendocrine
component represented 10%–30% of the tumor, while in two (one non-mucinous breast and one poorly
differentiated gastric adenocarcinoma) cases, the NE component exceeded the MiNEN defining 30% [5]
(pp. 18–19). TMA blocks were constructed with the manual TMA builder instrument (Histopathology
Ltd., Pécs, Hungary), as previously published [43]. Each tumor case in TMA blocks was represented
with at least two cores (central and peripheral regions) of 2 mm. To compare the proportion of positive
cases by the applied markers, Fisher’s exact test was performed.
All NENs were diagnosed and graded according to the WHO Blue Book [1], corresponding to
their anatomical location.
The study was performed in agreement with the guidelines of the Declaration of Helsinki for
human medical research and was ethically approved by the Clinical Research Coordination Office of
the University of Szeged (4430/2018) 7 January 2019.
4.2. Immunohistochemistry and Evaluation of Staining Patterns
The IHC reactions were uniformly performed in FFPE sections. Briefly, 2–5 µm-thick paraffin
sections were routinely de-waxed, blocked for endogenic peroxidase activities in ethanol containing
1.5% (v/v) H2O2, and heat-treated in 10 mM Sodium citrate (0.05 % Tween-20, pH 10.0) antigen retrieval
buffer using a household electric pressure cooker. After protein blocking in 50 mM Tris-buffered saline
(TBS, pH 7.4) containing 5% (w/v) low-fat milk powder, the sections were incubated with the primary
antibodies at room temperature for 70 min. Detection was performed using the Novolink polymer
kit (Leica Biosystems/Novocastra, Newcastle Upon Tyne, United Kingdom), and nuclear staining
was carried out with Mayer’s hematoxylin. The IHC stains were executed by a four-channel TECAN
Freedom Evo liquid handling platform (TECAN, Mannedorf, Switzerland).
For STX1, we utilized a well-characterized mouse monoclonal antibody HPC-1 (sc-12736; 1:200;
Santa Cruz Biotechnology, Dallas, TX, USA), which detects both STX1 A and B isoforms. A tumor
sample was considered to be STX1-positive if more than 50% of the neoplastic cells showed either
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membranous or cytoplasmic staining. The staining intensity was categorized as weak, moderate,
or strong. Samples were independently assessed by three of the authors (S.T-N., B.K., and L.K.).
In a case with discordant results, a consensus was reached by a second-look evaluation made jointly.
In NENs investigated using the TMA technique, immunostainings for the most common NE
markers, such as SYP (27G12; 1:100; Leica Biosystems), CHGA (5H7; Leica Biosystems/Novocastra,
Newcastle Upon Tyne, United Kingdom), and CD56 (MRQ-42; 1:500; Cell Marque, Rocklin, CA,
USA), were also performed to compare the results with STX1 expression. In cases where STX1
immunostainings were performed on whole tissue sections, the SYP, CHGA, and CD56 expression
was not tested systematically; however, the SYP, CHGA, and CD56 immunostainings performed
for the original pathology report were re-evaluated, if available. Cytoplasmic staining for SYP
and CHGA or membranous staining for CD56 were considered positive. To identify the various
subtypes of gastrointestinal NETs, IHC reactions were performed against VMAT1 (RMT77; 1:100; Leica
Biosystems/Novocastra, Newcastle Upon Tyne, United Kingdom) as a marker of EC cells and GLP1
(sc-57166; HYB 147-06; 1:100; Santa Cruz Biotechnology, Dallas, TX, USA) as a marker of L-cells. The
sustentacular cell population in paragangliomas and pheochromocytomas was identified with S100.
5. Conclusions
In conclusion, we showed that STX1 outperforms common NE IHC markers in terms of its
specificity and sensitivity and appears to be the most advantageous immunophenotypic marker of
NE cells and NENs. STX1 demonstrated a near-perfect specificity and an outstanding sensitivity,
even in NECs. We recommend that STX1 be added to the IHC panel of NE differentiation in routine
diagnostic histopathology. The consistent STX1 expression in all NETs, regardless of the anatomical
site or subtype, makes it a reliable marker, even in the hands of routine pathologists who are less
experienced with NENs and unaware of the specific expression patterns and possible pitfalls of classic
NE markers.
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